OptiCell Solutions – A Key Player in Cell and Gene Therapy

PRESSRELEASE

“OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg”

Flemingsberg Science Foundation, Huddinge, Sweden 18-Nov-2024

Flemingsberg continues to be a natural choice for knowledge-intensive and innovative businesses. OptiCell Solutions is a company that recently launched its operations at Novum Labs on the Flemingsberg Campus. Founded in 2024 by specialists from Karolinska University Hospital and entrepreneurs from the Life Science industry, the company specializes in improving the availability of high-quality target cells for cell and gene therapies, a critical component of the growing ATMP (Advanced Therapy Medicinal Products) sector.

Collecting High-Quality Target Cells – A Bottleneck

“Rapid access to high-quality cells can save lives,” says Jarmo Henriksson, CEO and the visionary founder of the newly established company OptiCell Solutions. Using advanced apheresis technology*, OptiCell Solutions enables the collection of cells from voluntary study participants, cell donors, and patients without delays.

“We aim to enhance access to new treatment options for patients with chronic diseases, offering our services to biotech companies, pharmaceutical companies, medical technology firms, CROs, and healthcare providers,” explains Jarmo Henriksson.

Flemingsberg – A Strategic Choice

OptiCell Solutions has chosen Flemingsberg as the base for its operations, a hub for innovation in Life Science and a growing ATMP cluster. Located near the Karolinska ATMP Center and Karolinska University Hospital, and within the flexible laboratory hotel Novum Labs, the company benefits from proximity to leading research and healthcare institutions.

“This geographical location supports the company’s vision of simplifying cell collection and accelerating the development of cell and gene therapies.”

Patient-Centered and Efficient Approach

OptiCell Solutions’ technology, called leukapheresis, enables the gentle and efficient collection of necessary cells. This method can yield at least 20 times more target cells compared to standard blood donations, while returning the blood to the donor for increased safety.

“At OptiCell Solutions, we prioritize creating a safe and comfortable environment for cell donors. With our apheresis technology, bright facilities, and comfortable treatment chairs, we ensure high-quality cell materials while providing a positive experience for donors,” says Jarmo Henriksson.

What Are Your Future Goals?

“OptiCell Solutions’ long-term goal is to become a leading player in cell collection for cell and gene therapies. We see great potential in Flemingsberg as a future center for innovation and collaboration within Life Science,” says Jarmo.

Finally, Jarmo shares that OptiCell Solutions also envisions supporting the development of precision medicine by ensuring access to high-quality target cells across Europe, a crucial factor for the success of biological drugs and innovative treatments.

*Apheresis technology involves separating blood into its components using centrifugation during ongoing leukapheresis.

OptiCell Solutions – A Key Player in Cell and Gene Therapy Establishes in Flemingsberg – Flemingsberg Science

— END PRESSRELEASE—

For more information, please contact
General Manager, Jarmo Henriksson, +46 (0) 73 699 48 37, jarmo.henriksson@opticellsolutions.com
Chairman of the board, Peter Rybäck, +46 (0) 73 849 07 96, peter.ryback@opticellsolutions.com

About OptiCell Solutions
Founded in 2024, OptiCell Solutions AB specializing in the field of apheresis and cell collection for cell and gene therapy (CAGT). By using our advanced apheresis technology, we can collect large quantities of specific donor cells, significantly advancing CAGT applications within in the biotech and healthcare sector. Furthermore, our extensive experience and know-how in apheresis enable us to offer specialized therapeutic apheresis services to the healthcare sector.

Located near the Karolinska University Hospital in Huddinge we aim to bridge the gap in resources by offering innovative solutions that enhance the availability of essential cells for cutting-edge research and life-saving therapies. With our deep expertise in apheresis technology and a strong commitment to ethical research practices, we are dedicated to improving patient outcomes and supporting the development of next-generation therapies for cancer care, autoimmune diseases, and other severe medical conditions.

At OptiCell Solutions, we strive to be at the forefront of medical innovation, providing the tools and services necessary to accelerate the transition to more effective and patient-centred care. For more information visit our website, www.opticellsolutions.com and follow us at LinkedIn.